{
}
Paris has imposed strict penalties on Opella, a paracetamol manufacturer, to ensure it maintains production and jobs in France following its acquisition by US firm CD&R. The agreement includes a €40 million penalty for halting production at key factories and a €100 million fine for not sourcing paracetamol ingredients from a future French facility. The French government will also invest up to €150 million in Opella to secure oversight of its operations.
The French government has secured strong guarantees in the sale of a 50% stake in Opella, producer of Doliprane, to American investment fund CD & R, which aims to enhance growth. The agreement includes a €70 million investment in France, job protection, and penalties for production stoppages. Sanofi retains a 48% stake, ensuring continued involvement in Opella's operations.
Sanofi is set to classify Opella's business as discontinued operations following a transaction expected to close in Q2 2025, impacting its financial reporting. The company anticipates a low single-digit percentage growth in business EPS for 2024, excluding Opella, while maintaining its focus on shareholder returns and external growth opportunities. Sanofi continues to prioritize innovation in healthcare, aiming to enhance lives globally through scientific advancements.
Sanofi has agreed to sell a controlling stake in its consumer health unit Opella to U.S. private equity firm Clayton Dubilier & Rice for approximately 15 billion euros. The deal includes guarantees for job and production retention in France, with the French public investment bank Bpifrance acquiring a 1% stake. This move follows concerns from labor unions about potential job losses amid the sale.
Paris has approved a €15 billion sale of paracetamol manufacturer Opella to a US fund, securing guarantees for its continued operation and development in France. Despite political concerns over potential job losses and supply chain impacts, the government believes foreign investment is crucial for enhancing the country's pharmaceutical sector. An investment screening will follow the agreement, which involves Sanofi and the American buyer.
The French government has reached a tripartite agreement with Sanofi and the American investment fund CD&R for the sale of the Opella subsidiary, which markets Doliprane. The deal includes strong guarantees for maintaining production in France, with a commitment to produce 250 million boxes annually and significant penalties for non-compliance. CD&R will invest €70 million over five years, while the French state will hold a minority stake through Bpifrance to ensure governance and adherence to the agreed conditions.
Roche is shifting its R&D focus towards major diseases like obesity and diabetes, responding to rising healthcare costs and government demands for cost-effective treatments. The company aims to develop transformative drugs for chronic illnesses, anticipating that these areas will account for over 50% of the global disease burden in the next decade. With the obesity drug market projected to exceed $100 billion annually by 2030, Roche's renewed investment includes a $2.7 billion acquisition of Carmot Therapeutics to bolster its cardiovascular-metabolic research.
UBS has upgraded its rating for Sanofi to "Buy," setting a target price of 110 euros. Analyst Carl Walton highlighted that the neurodermatitis drug Dupixent is expected to drive growth for the company in the third quarter, with acceleration anticipated in 2025.
UBS has upgraded Sanofi to a 'Buy' rating with a target price of 110 euros, citing the neurodermatitis drug Dupixent as a key growth driver for the company in the third quarter. Analyst Carl Walton anticipates that growth will accelerate further in 2025.
UBS has maintained a "Buy" rating for Sanofi, setting a price target of 110 euros ahead of the company's upcoming financial results. Analyst Carl Walton highlighted that the neurodermatitis drug Dupixent is expected to drive growth for the pharmaceutical firm in the third quarter, with acceleration anticipated in 2025.
Sanofi
Companies
| Symbol | SNY |
| Name | Sanofi |
| Currency | USD |
| Sector | Health Care |
| IndustryGroup | Pharmaceuticals, Biotechnology & Life Sciences |
| Industry | Pharmaceuticals |
| Market | NASDAQ Global Select |
| Country | France |
| State | |
| City | Paris |
| Zipcode | 75008 |
| Website | http://www.sanofi.com |
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
France imposes penalties on Opella to retain jobs and production after takeover
13:28 21.10.2024
French government secures guarantees in sale of Doliprane to US fund
Euro
Rexel S.A.
SPIE SA
Seqens
Sanofi
CD & R
USA
CHN
FRA
Marc Ferracci
Nicolas Dufourcq
Paul Hudson
Antoine Armand
Show more
11:05 21.10.2024
sanofi announces strategic transaction to enhance consumer healthcare business potential
Euro
United States Dollar
British Pound Sterling
CD&R Blossom Holdings LP
Sanofi
FRA
Sandrine Guendoul
Victor Rouault
Evan Berland
Nicolas Obrist
Léo Le Bourhis
Show more
07:31 21.10.2024
Sanofi agrees to sell consumer health unit to Clayton Dubilier and Rice
Euro
Clayton, Dubilier & Rice LLC
Sanofi
USA
FRA
Diane Craft
Richard Lough
Juliette Jabkhiro
Antoine Armand
Ros Russell
Show more
23:31 20.10.2024
France approves 15 billion euro sale of paracetamol maker to US fund
22:00 20.10.2024
French government secures stake in Sanofi subsidiary for Doliprane production guarantees
Euro
CD&R Blossom Holdings LP
Sanofi
FRA
USA
Marc Ferracci
Antoine Armand
Nicolas Dufourcq
Laurent Saint-Martin
Show more
20:43 20.10.2024
pharmaceutical companies shift focus to cost-effective treatments amid rising healthcare expenses
Euro
United States Dollar
Novartis AG
Novo Nordisk A/S
Bayer AG
Johnson & Johnson
Hoffmann-La Roche AG
Sanofi
DEU
DNK
CHE
USA
FRA
Mike Rea
Novo Nordisk
Bill Coyle
Nerys Avery
Thomas Schinecker
Show more
10:00 20.10.2024
ubs upgrades sanofi to buy with target price of 110 euros
11:57 18.10.2024
ubs upgrades sanofi to buy with target price of 110 euros
11:57 18.10.2024
UBS maintains buy rating for Sanofi with price target of 110 euros
11:09 18.10.2024
Trending
Subcategory
Industry Trends
Corporate News
Global Trade Developments
Government Economic Policies
Supply Chain Management
Startups & Entrepreneurship
Retail and Consumer Goods
Energy Sector Developments
Cryptocurrency & Blockchain Regulations
Emerging Startups
Funding Rounds & Investments
Industry Mergers & Acquisitions
Banking & Investment Regulations
Stock Market Updates
Anti-Money Laundering (AML) Regulations
Tax Policy & Corporate Taxation
CEO Changes
Foreign Exchange Rates
Financial Scams and Security
Finance Mergers & Acquisitions
Countries:
Companies:
Apple Inc.
Learning Resources Inc.
MGA Entertainment Inc.
State Street Global Advisors Luxembourg SICAV - SSGA EMU ESG Screened Equity Fund
European Union Bonds
SLB 4,6% 01JUN25
Equinor Ventures AS
Quanta Services, Inc.
Gold Circuit Electronics Ltd.
Unimicron Technology Corp.
Yatra Online, Inc.
Daiwa Institute OF Research Ltd.
Pegatron Corporation
KODEX India Tata Group
Wistron Corporation
Foxconn Technology Co., Ltd.
Volkswagen AG
XIAOMI-W
XPeng Inc.
Tesla, Inc.
Currencies:
United States Dollar
Chinese Yuan
Indian Rupee
United Arab Emirates Dirham
Japanese Yen
Vietnamese Đồng
New Taiwan Dollar
Euro
Australian Dollar
Thai Baht
Saudi Riyal
People: